Format

Send to

Choose Destination
Curr Drug Saf. 2010 Oct;5(4):287-92.

Immunogenicity and its impact on benefit/risk considerations in the authorisation of biopharmaceuticals.

Author information

1
Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany. bueis@pei.de

Abstract

Antibody formation is an intended physiological reaction to a "non-self" protein intentionally triggered in the case of vaccines. However, an unwanted immune response to a therapeutic protein may lead to a loss of efficacy and/or to severe side effects. The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) issued a multidisciplinary guideline providing general recommendations from a marketing authorisation perspective on how to systematically assess an unwanted immune response following the administration of a biological drug. In this article, we discuss key aspects of this guideline and its concept, with a particular focus on the impact of immunogenicity on benefit/risk estimation of a therapeutic protein.

PMID:
20615175
DOI:
10.2174/157488610792245993
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center